

UAE's Julphar delays drug plant plan over registration obstacles

UAE drugmaker Julphar eyes EGP 400 million in sales by the end of 2018. The company set a 16% sales growth target and plans to launch four new drugs in 2019. The company has decided to delay its plan to establish a pharmaceutical plant in Egypt, citing bureaucratic obstacles affecting drug registration processes.